<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In Nordic countries, the standard treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) in the adjuvant setting is bolus <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) plus leucovorin alone or in combination with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>5-FU competes with the natural occurring <z:chebi fb="0" ids="16898">pyrimidine</z:chebi> <z:chebi fb="0" ids="17568">uracil</z:chebi> (<z:chebi fb="0" ids="17568">Ura</z:chebi>) as a substrate for dihydropyrimidine dehydrogenase (DPD; enzyme commission number 1.3.1.2) </plain></SENT>
<SENT sid="2" pm="."><plain>Low DPD activity is associated with toxicity during treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Pretherapeutic detection of <z:e sem="disease" ids="C0268132" disease_type="Disease or Syndrome" abbrv="">DPD deficiency</z:e> could prevent severe toxicity otherwise limiting drug administration </plain></SENT>
<SENT sid="4" pm="."><plain>Assays showing that <z:e sem="disease" ids="C0268132" disease_type="Disease or Syndrome" abbrv="">DPD deficiency</z:e> impairs breakdown of <z:chebi fb="0" ids="17568">Ura</z:chebi> to dihydrouracil (UH(2)) seem promising for clinical use </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: Urine was collected from 56 untreated volunteers and 143 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> before adjuvant treatment </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="17568">Ura</z:chebi> and UH(2) were analyzed using a column-switching high-performance liquid chromatography method that incorporates reversed-phase and <z:chebi fb="36" ids="36916">cation</z:chebi>-exchange columns </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="17568">Ura</z:chebi>, UH(2), and UH(2)/<z:chebi fb="0" ids="17568">Ura</z:chebi> levels were related to toxicity </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: <z:chebi fb="0" ids="17568">Ura</z:chebi> and UH(2) in patients were not different from controls </plain></SENT>
<SENT sid="9" pm="."><plain>UH(2) was significantly higher in women compared with men </plain></SENT>
<SENT sid="10" pm="."><plain>The UH(2)/<z:chebi fb="0" ids="17568">Ura</z:chebi> ratio, however, did not differ according to sex </plain></SENT>
<SENT sid="11" pm="."><plain>Low UH(2) and UH(2)/<z:chebi fb="0" ids="17568">Ura</z:chebi> levels were associated with <z:hpo ids='HP_0002014'>diarrhea</z:hpo> in men </plain></SENT>
<SENT sid="12" pm="."><plain>Women experiencing <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> had significantly higher <z:chebi fb="0" ids="17568">Ura</z:chebi> compared with women with no <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>The UH(2)/<z:chebi fb="0" ids="17568">Ura</z:chebi> ratio correlated negatively with total toxicity score in men (r = -0.39, P = .020) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: Pretherapeutic <z:chebi fb="0" ids="17568">Ura</z:chebi> and UH(2) levels per se may be related to risk of side effects during adjuvant 5-FU-based treatment, whereas the UH(2)/<z:chebi fb="0" ids="17568">Ura</z:chebi> ratio may not always reveal such a risk </plain></SENT>
<SENT sid="15" pm="."><plain>Sex is a strong risk factor for toxicity, showing the importance of evaluating male and female patients separately </plain></SENT>
</text></document>